药物基因组学与哮喘治疗:儿童、家庭及医护人员的接受度
多数参与者(80.0%)接受「个性化遗传哮喘方案」,但儿童青少年、家长与医护人员之间在数据重要性与隐私看法上存在明显差异。
要点
- 多数参与者(80.0%)接受基于遗传信息的个性化哮喘方案。
- 个人信息被视为最重要(47.5%)和最私密(40%),但各组间差异大。
- 84.0%认为应告知儿童青少年遗传数据共享,多数认为应在12岁前开始。
核心结论
- 用遗传信息指导儿童青少年哮喘管理在儿童青少年、家长/监护人和医护人员中总体接受度较高,但三类人群观点存在关键差异。
主要发现
- 50份回收问卷包括26例儿童青少年(5–11岁10例、12–15岁11例、16–18岁5例)、13名家长和11名医护人员。
- 对所有类型数据,个人信息被评为最重要(n=19,47.5%)和最私密(n=16,40%),但各组间差异较大。
- 在健康数据中,过敏信息被评为最重要(n=12,30.8%),心理健康记录被评为最私密(n=21,53.8%),各组间同样存在差异。
- 「个性化遗传哮喘方案」总体获多数参与者接受(n=40,80.0%)。
临床怎么用
- 向儿童青少年、家长和医护人员推行遗传信息指导的哮喘管理时,可预期总体接受度较高,但需顾及三类人群对数据重要性与隐私的不同看法。
- 共享儿童青少年遗传数据时,应告知儿童青少年本人,多数参与者认为告知宜在12岁前开始。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence supporting personalised treatment for asthma based on an individual's genetics is mounting. The views of children and young people (CYP), parents and healthcare professionals (HCPs) about this evolution of clinical care are not known. METHODS: A pilot prospective questionnaire-based study was undertaken of CYP with asthma, their parents and HCPs at a secondary/tertiary children's hospital in the UK. RESULTS: Fifty-nine questionnaires were distributed and 50 returned (response rate 84.7%), comprising 26 CYP (10 were 5-11 years, 11 were 12-15 years and 5 were 16-18 years old), 13 parents and 11 HCPs. For all types of data, personal information was ranked as the 'most important' (n=19, 47.5%) and 'most private' (n=16, 40%), but with considerable variation across groups. Within health data, allergies were rated as 'most important' (n=12, 30.8%), and mental health records the 'most private' (n=21, 53.8%), again with variation across groups. A 'personalised genetic asthma plan' was acceptable to the majority overall (n=40, 80.0%). With regard to sharing CYP's genetic data, 23 (46%) of participants were happy for unconditional sharing between HCPs, and 23 (46%) agreed to sharing solely in relation to the CYP's asthma management. Forty-two (84.0%) of participants felt CYP should be informed about genetic data being shared, and the majority felt this should commence by 12 years of age. CONCLUSION: The use of genetic information to guide management of asthma in CYP is largely acceptable to CYP, parents/guardians and HCPs. However, there are key differences between the opinions of CYP, parents and HCPs.
引用
- Parry CM, Seddon G, Rogers N, et al. Pharmacogenomics and asthma treatment: acceptability to children, families and healthcare professionals. Arch Dis Child. 2022. PMID: 35074833. doi:10.1136/archdischild-2021-322396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。